Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The purpose of this study was to compare alpha-L-fucosidase and alpha-fetoprotein as serum markers of
hepatocellular carcinoma
in 72 southern African blacks with this tumour and 64 matched patients with benign hepatic diseases which might be mistaken clinically for
hepatocellular carcinoma
.
Alpha-L-fucosidase
activity was assayed using p-nitrophenyl-L-fucopyranoside (pNpf) as a substrate and alpha-fetoprotein concentrations were measured by radioimmunoassay. Serum alpha-L-fucosidase activity in the patients with
hepatocellular carcinoma
(mean 1,268, s.e.m. +/- 83.7, median 1,150 and range 38-3,698 nmol pNpf ml-1 h-1) was significantly higher than that in the matched controls (mean 798, s.e.m. +/- 65.8, median 648 and range 273-3,825 nmol pNpf ml-1 h-1) (P = 0.0001). However, alpha-L-fucosidase was both less sensitive (75 versus 87%) and less specific (70 versus 87%) than alpha-fetoprotein as a serum marker of
hepatocellular carcinoma
. When, in an endeavour to eliminate false-positive results, the diagnostic cut-off level for alpha-L-fucosidase was increased to 1,500 nmol pNpf ml-1 h-1 and for alpha-fetoprotein to 400 ng ml-1, the sensitivity of alpha-L-fucosidase fell to 21% whereas that of alpha-fetoprotein remained satisfactory at 78%. If the two markers were used together, the number of false-negative alpha-fetoprotein results was reduced from 13 to 5.5%. We conclude that alpha-L-fucosidase is less useful than alpha-fetoprotein as a single marker of
hepatocellular carcinoma
in southern African blacks. However, the two markers can profitably be used together.
...
PMID:Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in southern African blacks. 246 86
Alpha-fetoprotein (AFP) is the primary marker for detecting
hepatocellular carcinoma
(
HCC
) and has been used widely in the clinic, but AFP is a biomarker characterized by poor sensitivity and specificity.
Alpha-L-fucosidase
(
AFU
) has been proposed as a tumor marker for diagnosis of
HCC
in many studies. However, conclusions of its diagnostic value are inconsistent. The current review aimed to evaluate the diagnostic value of
AFU
for
HCC
. After systematic review of 12 related studies, sensitivity, specificity, and diagnostic odds ratio (DOR) were pooled using random-effect models. Summary receiver operating characteristic (sROC) curve analysis was used to summarize the overall test performance. The pooled sensitivity for
AFU
was 0.72 (95% confidence interval (CI) 0.69-0.76), while the pooled specificity was 0.78 (95% CI 0.74-0.81). DOR was 10.26 (95% CI 5.99-17.59), and the area under the curve (AUC) was 0.8125.
AFU
had great value for the diagnosis of
HCC
as a serum marker.
...
PMID:Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis. 2439 55
